Coronavirus

Across the private equity industry, the impacts of the pandemic-spurred economic downturn are being felt in dealmaking, which has slowed or paused fundraising processes while LPs work to understand the status of their portfolios.

COVID-19 crisis could bode well for new M&A tech opportunities and Gryphon launches sixth fund.

Available capital and promise of consumer staples keep sponsors around but most companies will not seal deals in the near term.

While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.

Amid the COVID-9 crisis, some firms are invoking the MAC clause to pull out of deals.

The turnaround expert shares his take on covid-19's impact on PE, asserting that he's seeing MAC clauses implemented for the first time in his 20-year career.

Thoma Bravo calls off its potential $2 billion-plus sale of Imprivata amid the coronavirus pandemic and New York State Common Retirement Fund commits to a $2 billion co-investment fund with Neuberger Berman.

Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.

MiddleGround is paying leave for employees who test positive for COVID-19 and trying to de-stress during a period of excessive stress.

Areas of the healthcare industry will likely be triggered into action, spurring innovation, as bottlenecks in the system become increasingly clear amid covid-19, Adams told PE Hub.